ADMA Biologics announces commercial relaunch and first commercial sales of BIVIGAM®
ADMA Biologics announces the commercial relaunch and its first commercial sales of BIVIGAM®. BIVIGAM® had a BLA manufacturing change PAS approved by the FDA May 9, 2019, enabling ADMA to resume marketing BIVIGAM® to US- based prescribers and healthcare professionals. August 22, 2019